Purpose: The purpose of this study is to improve upon a recently introduced bi-objective treatment planning method for prostate high-dose-rate (HDR) brachytherapy (BT), both in terms of resulting plan quality and runtime requirements, to the extent that its execution time is clinically acceptable. Methods: Bi-objective treatment planning is done using a state-of-the-art multiobjective evolutionary algorithm, which produces a large number of potential treatment plans with different trade-offs between coverage of the target volumes and sparing organs at risk. A graphics processing unit (GPU) is used for large-scale parallelization of dose calculations and the calculation of the dose-volume (DV) indices of potential treatment plans. Moreover, the objectives of the previously used bi-objective optimization model are modified to produce better results. Results: We applied the GPU-accelerated bi-objective treatment planning method to a set of 18 patients, resulting in a set containing a few hundred potential treatment plans with different trade-offs for each of these patients. Due to accelerations introduced in this article, results previously achieved after 1 hour are now achieved within 30 seconds of optimization. We found plans satisfying the clinical protocol for 15 of 18 patients, whereas this was the case for only 4 of 18 clinical plans. Higher quality treatment plans are obtained when the accuracy of DV index calculation is increased using more dose calculation points, requiring still no more than 3 minutes of optimization for 100 000 points. Conclusions: Large sets of high-quality treatment plans that trade-off coverage and sparing are now achievable within 30 seconds, due to the GPU-acceleration of a previously introduced bi-objective treatment planning method for prostate HDR brachytherapy. Higher quality plans can be achieved when optimizing for 3 minutes, which we still consider to be clinically acceptable. This allows for more insightful treatment plan selection in a clinical setting.
INTRODUCTION
Treatment planning for prostate high-dose-rate (HDR) brachytherapy (BT) 1 consists of finding a specific dwell time for each dwell position, such that a desirable dose distribution is achieved. The main difficulty of treatment planning comes from the fact that the target volume(s) should receive sufficient dose, while the surrounding organs at risk (OARs) should receive as little dose as possible. For this reason, some form of automated optimization is often used to find a set of dwell times such that all clinical criteria are satisfied, or are as close as possible to being satisfied. Such clinical criteria are generally defined in terms of dose-volume (DV) planning criteria (see Section 2.C).
Despite the fact that a treatment plan is often evaluated based on its DV indices, inverse planning methods frequently used in clinical practice do not directly optimize the DV indices. 2, 3 Instead, for the purpose of efficiency, a penaltybased approach is used, which aims to minimize the sum of penalty values of all dose calculation (DC) points, with a penalty value assigned to a DC point when the dose at that point is outside the range of acceptable dose values. This reformulated problem is then optimized using, for example, simulated annealing, 3 linear programming, 4 or the Broyden-Fletcher-Goldfarb-Shanno (BFGS) algorithm. 2 It was previously shown that such a penalty-based problem formulation weakly correlates with the quality of DV indices. 5 The optimal solution to a penalty-based problem formulation may not satisfy all clinical criteria, even if such a treatment plan does exist for the respective patient. Furthermore, finding optimal patient-specific weights for a penalty-based problem formulation is an arguably unintuitive and labor-intensive process.
Several studies have looked into directly optimizing DV indices using linear programming, 6 mixed-integer linear programming, 5 simulated annealing, 7 or evolutionary algorithms. 8 These approaches generally solve a relaxed version of the problem, or use a small number of dose calculation points, because solving plans to optimality directly using DV indices is known to take far too long for clinical practice, 7 necessitating state-of-the-art modern heuristics.
A core aspect of the difficulty of brachytherapy planning is caused by the inherent trade-off between tumor coverage and organ sparing, that is, any increase in dose to the target volumes also leads to an increase in dose to the OARs.
In order to gain more insight into the trade-off between coverage and sparing, a bi-objective treatment planning model and optimization method was previously introduced. 8 Multi-Objective Evolutionary Algorithms (MOEAs) are known to be among the state of the art when dealing with problems involving two or three conflicting objectives. 9 MOEAs are capable of finding large sets of potential solutions, with each solution having a different trade-off between the objectives of interest, that is, tumor coverage and organ sparing in this scenario. The optimization of a set of treatment plans allows for more insightful treatment plan selection, as it is directly clear how much sparing needs to be sacrificed in order to improve the tumor coverage by a certain amount. This can be especially useful in cases where it is not possible to satisfy all criteria defined in the clinical protocol, for example, due to suboptimal catheter placement, making it more difficult to find a desirable trade-off between coverage and sparing.
The aforementioned bi-objective treatment planning method uses a novel MOEA, named MO-RV-GOMEA, 10 as it performed better than other state-of-the-art MOEAs. 8 Moreover, in a recent observer study for 18 prostate cancer patients with three physicians as observers, plans resulting from this approach were found to be preferable compared to plans resulting from the current clinical workflow at our clinic. 11 However, this treatment planning method requires approximately 1 hour of computation time on a single CPU core, exceeding the acceptable amount of computation time in clinical practice.
In this article, we improve the quality of plans found by the previously introduced bi-objective treatment planning method 8 by improving the optimization model and method, and we accelerate the method to the extent that its execution time is clinically acceptable. Specifically, we apply largescale parallelization on a graphics processing unit (GPU). By doing so, the method is sped up so much that it can even be used to intrinsically improve the approach by increasing the number of so-called dose calculation points used for calculating the DV indices, decreasing the effect of overfitting and increasing the quality of treatment plans.
MATERIALS AND METHODS

2.A. Data
A dataset of 18 patients with intermediate-and high-risk prostate cancer, previously treated at the Amsterdam UMC in Amsterdam, the Netherlands, is used for all experiments in this article. These patients were treated between February 2015 and April 2017 with external beam radiotherapy on the prostate and base of the seminal vesicles to a dose of 44 Gy in daily fractions of 2.2 Gy followed by a single dose of 13 Gy HDR brachytherapy on the prostate. A median of 16 (range: 14-20) catheters were implanted, resulting in a median of 413 (range: 250-668) dwell positions. Catheter reconstruction and contouring of Regions Of Interest (ROIs) were done on three orthogonal pelvic T2-weighted turbo spin echo MRI (Ingenia 3 T Philips Healthcare, Best, the Netherlands) scans with a resolution of 0.52 9 0.52 mm, and a slice thickness of 3.0 mm with a 0.3 mm gap. Three interpolated contours were added between each contoured slice of each ROI. The clinical plans that these patients were treated with were obtained through optimization with IPSA 3 or HIPO 2 using a standard set of objectives, followed by graphical optimization.
2.B. Clinical protocol
In clinical practice, the quality of a treatment plan is often assessed in terms of the DV histogram or a set of DV indices, and a visual inspection of the dose distribution. Table I .
2.C. DV index estimation
DV indices are generally estimated using a randomly generated (Monte Carlo-sampling) or a regularly distributed set of DC points. 12 When using Monte Carlo-sampling, ROIs are 
represented by a large set of DC points d, with d i describing the total dose received by the DC point with index i. 
For an accurate estimation of DV indices, using a sufficiently large set of DC points is necessary. 12 This is especially important when DV indices are directly optimized using automated treatment planning, as this approach is prone to overfitting. This means that DV indices optimized using a certain set of DC points will always become worse when recalculated using a larger, more representative, set of DC points. The larger the set of DC points used for optimization, the more accurate the DV index calculation, and the smaller the effect of overfitting. Using a larger set of DC points does however increase the computational effort to estimate DV indices, making the optimization procedure more time consuming. Since the dose in all DC points can be calculated independently, the efficiency of DV index estimation can be greatly increased by the use of a GPU.
In this article, the reported DV indices of any optimized plan are recalculated after optimization on a set of 500 000 independently sampled DC points, identical to the standard setting in Oncentra Brachy (version 4.5, Elekta AB, Stockholm, Sweden).
In Section 3.A, we show how the number of DC points affects treatment plan quality of the automated treatment planning method used in this article.
2.D. Bi-objective treatment planning model
Previously, we proposed a bi-objective optimization approach 8, 13 using two objectives that are directly defined in terms of the DV indices of a treatment plan. Dwell times of all activated dwell positions, those within a target volume plus 5 mm margin and outside of the urethra plus 1 mm margin, are optimized. This optimization approach was previously validated in a retrospective observer study, 11 showing that plans produced by solving this bi-objective model with the multiobjective evolutionary algorithm GOMEA 10 were preferred over the clinically used plan in all cases.
The two objectives of the bi-objective optimization model, the least coverage index (LCI) and least sparing index (LSI), quantify how much the DV indices of a treatment plan deviate from the aspiration values specified in the clinical protocol, with regard to tumor coverage and organ sparing, respectively. Positive values for either LCI or LSI indicate that the clinical protocol has been satisfied with regard to coverage or sparing, respectively.
Given the protocol in Table I 
where are excluded from the LSI, as is done in previous work, 8 because these volume indices have a different unit than the remaining dose indices in the LSI, making them difficult to be compared to each other. Instead, the aspiration values for these volume indices are included as hard constraints, meaning that any plan produced by the optimization procedure must satisfy these aspiration values. Furthermore, the clinical criterion D prostate 90
[ 100% is not included in the LCI, because this criterion is always satisfied when V prostate 100
[ 95% is satisfied. A benefit of optimizing the LCI and LSI is that their outcome strictly depends on the most violated DV index, which is the DV index with the lowest corresponding DV delta. All optimization effort is therefore spent on trying to optimize the most violated DV index. However, this means that any small improvement of the most violated DV index will be preferred over a much larger improvement of a different index, as long as this does not change which DV index is the most violated. Furthermore, optimization of remaining DV indices is no longer possible if the most violated DV index has reached its optimal value. Intuitively, it is desirable to spend some optimization effort on DV indices that are not the most violated, especially in the aforementioned cases. For this reason, we define adaptively weighted variations of LCI and LSI, denoted LCI w and LSI w .
To compute the LCI w , the required DV deltas are first sorted in descending (DESC) order to find the order of DV indices from least to most violated. For the LCI w , the sorted list of DV deltas is defined as 
ÞÞ:
Similarly, for the LSI w , the sorted list of DV deltas is defined as Given the sorted list of DV deltas, the LCI w and LSI w are then defined as a weighted sum of DV deltas, where the DV delta with the highest value, that is, corresponding to the least violated DV index, receives a weight of 1 and consecutive weights increase exponentially by a factor of k = 10. All weights are then normalized to the range between 0 and 1. Note that the weights associated with individual DV deltas are dynamic throughout optimization, because the sorted order may change, and are not set by a user.
LCI 
where rank r is a one-based index that indicates the position of the respective DV index in the sorted list of indices. For k = 1, LCI w and LSI w define equally weighted linear combinations of their respective DV deltas. This would result in a loss of focus on the most violated DV index, making it more difficult to find solutions satisfying all clinical criteria. As k increases, the importance of the most violated DV index is increased. For k approaching infinity, LCI w and LSI w are identical to the LCI and LSI. The value of k = 10 was empirically determined to produce equally good solutions in terms of LCI and LSI as the previously used bi-objective model, 8 while increasing the quality of DV indices that are not the most violated.
In this article, we use MO-RV-GOMEA with the LCI w and LSI w as optimization objectives, unless stated otherwise. Note that the LCI w and LSI w no longer have the property that a positive value indicates that all clinical criteria have been satisfied. For this reason, we generally report LCI and LSI in Section 3, even when LCI w and LSI w were used as optimization objectives.
In Section 3 .B, we analyze how the results of the optimization are affected by using the LCI w and LSI w as optimization objectives, compared to the LCI and LSI.
2.E. Multiobjective evolutionary algorithm
Evolutionary Algorithms (EAs) 14 are computational heuristics that can be distinguished by the fact that a set, called the population, of potential solutions is maintained, rather than a single solution. In our case, a population of 96 solutions is used, where each solution represents a treatment plan. The fitness of a solution, in this case defined in terms of LCI and LSI, defines its relative quality. During each generation of an EA, variation is applied in order to generate a set of new potential solutions, called the offspring. By applying selection, the solutions with the best fitness from the combined population and offspring form the population of the following generation, and non-selected solutions are discarded.
EAs are known to be among the state of the art in the field of multi-objective optimization. 9 The result of a multi-objective EA is a set of solutions that each have a different tradeoff with regard to the objectives. In this article, we specifically use the Multi-Objective Real-Valued Gene-pool Optimal Mixing Evolutionary Algorithm (MO-RV-GOMEA), 10 as it was shown to achieve the best performance among a set of state-of-the-art multiobjective EAs on bi-objective treatment planning for prostate HDR BT. 8 MO-RV-GOMEA uses an archive with a maximum capacity of 1250 to store all plans for which no better plan was previously found. In this context, we consider a plan to be better when it Pareto-dominates the other plan in terms of LCI and LSI, that is, it has a better LCI value and an LSI value that is at least as good, or vice versa. This archive is constantly updated whenever new plans are found. At the end of an optimization run, all plans in the archive are presented as the results of the optimization.
We refer the interested reader to Section S-A of the Supporting Information for detailed parameter settings of MO-RV-GOMEA.
2.F. GPU-accelerated bi-objective treatment planning
GPUs are widely used for the purpose of high-performance computing, both within the field of medical physics, 15 for example, for dose calculation, [16] [17] [18] [19] and in the field of evolutionary computation. [20] [21] [22] [23] Because the design of GPUs is particularly suited for specific forms of large-scale parallel computation, they are very suitable for high-performance dose calculation, as the dose in all DC points can be calculated in parallel.
By far the most time-consuming procedures of the bi-objective treatment planning method are the dose calculation and the calculation of the DV indices of the treatment plans in the population. Due to the use of an EA, these procedures are always performed on the entire population, further increasing the potential for parallelization. We therefore use a GPU to improve the performance of the population-wide dose and DV index calculation. Specifically, the GPU that is used in this work is an NVIDIA Titan Xp, and all programming for the GPU is done in CUDA. 24 Using an NVIDIA Titan Xp GPU, our treatment planning method currently supports the optimization of sets up to 500 000 DC points.
We use a parallel dose calculation method that we previously introduced. 25 In this method, the dwell times of all treatment plans in the population are stored in a matrix T, where each row describes the set of dwell times of one treatment plan. The dose in all DC points is then calculated through the matrix-matrix multiplication D ¼ TR T , where R is a dose-rate matrix according to the TG-43 model. 
is equal to the number of DC points.
The used optimization algorithm, MO-RV-GOMEA, 10 often finds new potential treatment plans by modifying a small number of dwell times of a potential treatment plan currently existing in the population. When this is the case, the dose distribution D 0 of the modified treatment plan is calculated more efficiently through D 0 ¼ D þ DTR T , with DT the matrix of differences in dwell times. 25 Matrix DT has few columns with non-zero elements, equal to the number of dwell times that have been modified. Only these columns with nonzero elements are considered for the calculation of D 0 . The estimation of dose indices requires sorting the dose in the DC points of each ROI for which a dose index must be calculated, for each potential treatment plan. For this purpose, each DC point d i is assigned an identifier ID i , such that DC points in the same ROI of the same treatment plan are assigned an identical ID. A list L of dose/ID pairs is then created, that is, L ¼ ½ðd 0 ; ID 0 Þ; ðd 1 ; ID 1 Þ; . . .. The Thrust library, 27 which contains a large number of CUDA utility functions, is then used to sort L by dose value in ascending order. This is followed by the Thrust stable sort procedure, sorting L by ID in ascending order. The stable sort procedure sorts L by ID, but maintains the relative order of items with an identical ID. As the dose values of L were previously sorted, this means that L will be sorted by ID, but dose values with the same ID remain sorted. The above two sorting procedures therefore result in a list of DC points that are firstly sorted by key, and secondly sorted by dose. A dose index is then calculated according to Section 2.C.
The estimation of volume indices requires counting the number of DC points that receive at least a certain dose. For this purpose, all required DC points are first compared to their respective aspiration value in parallel, resulting in a large array of Boolean values. Thrust is then used to compute a cumulative sum of this array, after which the number of points achieving their respective aspiration value can be trivially computed for any subsequence of this array. A volume index is then calculated according to Section 2.C.
The sampling of DC points and the creation of the doserate matrix are not included in the optimization times presented in this article. Dose points are sampled using four CPU cores in parallel, and the dose-rate matrix is calculated on a single CPU core and then copied to the GPU memory. For a set of 100 000 DC points, this takes approximately 2 seconds on average.
In Section 3.C, we compare treatment plans optimized with the GPU-accelerated bi-objective treatment planning to the set of clinical plans.
RESULTS
In Section 3.A, we show how the outcome of optimization in terms of LCI and LSI depends on the number of DC points. Section 3.B then shows the effect of the introduction of the LCI w and LSI w on the optimization. Finally, the quality of the results achieved by our bi-objective treatment planning method is shown in Section 3.C.
3.A. DV index estimation
In Fig. 1 , we illustrate the impact of the number of DC points on the optimization results. This figure shows the treatment plans found after completing 30 runs of the optimization with a time limit of 10 minutes on a set of 5000, 10 000, 20 000, 50 000, 100 000, and 200 000 DC points, respectively. A time limit of 10 minutes was used for all settings, as this time limit was found to be sufficient to obtain the maximum achievable performance for each of the tested number of DC points. Figure 1(a) shows the perceived LCI and LSI, calculated using sets of 5000, 10 000, and 20 000 DC points used for optimization. The perceived LCI and LSI values, that is, as computed by the optimization algorithm, suggest that better treatment plans can be found when smaller numbers of DC points are used. However, Fig. 1(b) shows a substantially more accurate calculation of the LCI and LSI values of the identical set of plans, using a set of 500 000 independently sampled DC points. Because Fig. 1(b) shows a reduction in LCI and LSI compared to Fig. 1(a) , this indicates that the quality of the resulting plans is substantially worse than perceived during optimization. This is caused by the fact that too small sets of DC points are not a good representation of their respective ROI. Due to this effect, no plan satisfying all clinical criteria was found for 8 of 30 runs when 5000 DC points were used for optimization. This was still the case for 2 of 30 runs when 10 000 DC points were used for optimization.
Figures 1(c) and 1(d) show that the difference between perceived and accurate LCI and LSI are much smaller when sets of at least 50 000 DC points are used for optimization. Furthermore, comparing Figs. 1(b) and 1(d) shows that the actual LCI and LSI obtained when solving for up to 20 000 DC points are clearly worse than the optimization algorithm perceives, whereas the difference between perceived and accurate LCI and LSI is much smaller for the set of 100 000 DC points.
As Fig. 1(d) shows a negligible difference between optimization outcomes for 100 000 and 200 000 DC points, a set of 100 000 DC points seems sufficiently large for a reliable calculation of the LCI and LSI during optimization. , showing that, for this patient, satisfying the clinical criterion for this index is possible regardless of the achieved LSI. Note that this is not the case for each patient, as shown in Figs. S1-S4, because this depends on the patient anatomy and catheter placement. As shown in Fig. 4 , it is still difficult to achieve good vesicle coverage for patient 1, and for various other patients for which results are shown in Figs. S1-S4 of the Supporting Information. Overall, however, the results indicate that optimizing the LCI w and LSI w leads to better results in terms of individual DV indices than optimizing the LCI and LSI.
3.B. Bi-objective treatment planning model
3.C. GPU-accelerated bi-objective treatment planning
We now show more detailed results obtained by optimizing for sets of 20 000 and 100 000 DC points, as the former setting was used when our bi-objective approach was introduced and validated, 8, 11 and the latter setting is one we decided upon in Section 3.A. Results obtained by optimizing for sets of 5000, 10 000, 50 000, and 200 000 DC points are included in Table SI of the Supporting Information. Furthermore, Table SII of the Supporting Information contains results for 20 000 and 100 000 DC points using time limits of 30, 60, 180, and 300 seconds. In Fig. 3 , we show the results of 30 optimization runs, each with a newly sampled set of DC points, for patients 1, 2, and 3, optimized on 20 000 and 100 000 DC points.
The optimization with 20 000 DC points resulted in a set of 461 treatment plans on average. After reevaluation using 500 000 DC points, 236 plans remained on average, as any plan was removed from the set of results when it was Paretodominated by a different plan. The optimization with 100 000 DC points resulted in a set of 658 treatment plans on average. After reevaluation using 500 000 DC points, 428 plans remained on average.
When 20 000 DC points are used for the optimization, results obtained after 30 seconds are similar to those obtained after 10 minutes. Furthermore, variation in LCI and LSI can be fairly large for this number of DC points. When 100 000 DC points are used, a clear increase in LCI and LSI is observed for time limits up to 180 seconds. Most importantly, there is little variation in the 30 different runs using 100 000 DC points, meaning that this number of DC points more reliably results in a set of high-quality treatment plans. Although there is still a minor difference between optimizing for 180 or 600 seconds, we argue that this difference can be considered irrelevant. Optimizing for 300 or 600 seconds could be considered depending on the strictness of clinical time constraints. Table II shows, for each patient used in this study, the clinical plan along with two plans selected from the result of the optimization on 20 000 DC points and 100 000 DC points. A time limit of 30 seconds was used for the optimization on 20 000 DC points, and 3 minutes for the optimization on 100 000 DC points. For both settings of the number of DC points, the optimization was performed 30 times per patient. The selected plan is the plan with the maximum achieved LCI that satisfied all sparing criteria, that is, achieved an LSI larger than 0. This plan is selected to show how much coverage can be achieved while all sparing criteria are satisfied. Although we show only one plan from each optimization run in Table II , each optimization run produced many plans with different trade-offs between coverage and sparing, as shown in Fig. 4 . Only 4 of 18 clinical plans satisfied all clinical criteria, whereas the optimization consistently (30 of 30 runs) found plans satisfying all clinical criteria for 15 of 18 patients. No plans satisfying the clinical protocol were found for the remaining three patients due to suboptimal catheter placement. The value of optimizing on a large number of DC points is mostly shown for patient 7, as all runs optimized on 100 000 DC points found a plan satisfying all clinical criteria, whereas this was not the case when optimizing 20 000 DC points.
A common characteristic of the clinical plans is that the urethra received a relatively large amount of dose, as the clinical criterion for the D 
DISCUSSION
In this article, we introduced a GPU-based acceleration of a previously introduced bi-objective evolutionary optimization approach for treatment planning for HDR prostate brachytherapy. This bi-objective treatment planning method directly optimizes DV indices, whereas conventional treatment planning methods, for example, IPSA 3 or HIPO, 2 use a penalty-based optimization model that weakly correlates with the quality of DV indices. 5 In contrast to a more recently introduced multicriteria optimization approach 28 that requires pretrained regression models to guide the optimization toward clinically acceptable plans, our bi-objective evolutionary optimization approach requires no prior training, Subfigures show all plans found by 30 independent optimization runs, to show variation, using a set of 100 000 DC points, and a time limit of 3 minutes. DV indices of the clinical plan are displayed as squares with identical colors (online version only) to the optimized treatment plans. In all subfigures, the (non-weighted) LCI and LSI are displayed, calculated using a set of 500 000 DC points.
because it directly calculates all relevant DV indices throughout optimization. As our bi-objective evolutionary optimization approach requires between 30 and 300 seconds, we have shown that it is indeed possible to approximate a surface of trade-off plans within a clinically acceptable time frame.
Increasing the accuracy of DV-index calculation by increasing the number of DC points further improves the DV indices achieved by the bi-objective optimization approach, with very good results obtainable in 3 minutes on 100 000 DC points. Even this more time-consuming approach is arguably still within the time limit of clinical practice, because planning in our clinic currently takes 30-60 minutes, which is mainly spent on graphical optimization. 11 Increasing the number of DC points beyond 100 000 would further increase the required computation time for a negligible increase in plan quality.
From Section 3.A, we conclude that a sufficient number of DC points should be used to prevent the optimization from overfitting and thus to make sure the most benefit is achieved from using inverse planning. For sets of at least 100 000 DC points, the effect of overfitting was found to be negligible. These results were found using points that were sampled uniformly at random in each ROI, because random sampling was previously found to be a better estimator of DV indices than sampling on a regular grid. 29 Other sampling techniques have previously been used, 6, 3 which could prove to require a smaller number of DC points for the accurate calculation of certain DV indices.
In this article, an equal number of DC points was sampled in each ROI, regardless of ROI volume. Preliminary experiments showed that distributing the DC points according to ROI volume resulted in plans with visibly worse LCI and LSI values. This is caused by the fact that LCI w and LSI w values mostly depend on the most violated DV index, and hence the number of DC points in the corresponding ROI. It is therefore valuable to have a relatively high number of DC points in the corresponding ROI of the most violated DV index. However, the ROI with the most violated DV index changes dynamically throughout optimization, and depends on many factors, including patient anatomy and clinical aspiration values. Further research is required to find a better distribution of DC points among ROIs, while avoiding a loss of obtained plan quality. The efficiency of the calculation of the values of the DV indices could also be improved by only using DC points in the rectum and bladder that are closest to the dwell positions, as these points are likely to receive the highest dose. 6 As the use of multi-objective EAs results in a set of tradeoff solutions, this inevitably leads to a decision-making process where a clinician must still decide which of the provided treatment plans is most suitable to actually use. Plots as in Fig. 4 can prove to be an aid for this decision-making process, as these plots help to visualize the trade-offs between all criteria of the clinical protocol, which should be complemented by the inspection of the dose distribution and dosevolume histograms for the evaluation of single plans. The plot showing only LCI and LSI can only give a rough indication of the trade-off between coverage and sparing, while the remaining plots tell the exact values of each DV index for a given LCI or LSI. Moreover, interactive software could further increase the intuitiveness of these plots by highlighting a selected treatment plan in all three plots. Note that the plots displayed in Fig. 4 display the combined results of 30 runs, for the sake of displaying the variation in the results of the optimization and the sampling of DC points, whereas a decision-maker would only see the results of one optimization run. Each run however covers the entire range of possible trade-offs shown in Fig. 4 .
Based on previous work 8 and the results in Section 3, we conclude that MO-RV-GOMEA is an algorithm that is excellently suited for direct DV-index based bi-objective treatment plan optimization. The best results were found when the optimization objectives were the LCI w and the LSI w , and a set of 100 000 DC points, that is, 20 000 DC points per ROI, was used. For this configuration, up to 3 minutes were required for the optimization, as no substantial improvements were found for time limits up to 10 minutes.
Topics of future research include generalization to optimization on different clinical protocols, for example, the American Brachytherapy Society consensus guidelines, 30 as the LCI and LSI could be constructed based on any clinical protocol consisting of a set of DV criteria. This also includes the addition of the V to the LSI, because these indices are currently included as hard constraints.
CONCLUSIONS
In general, bi-objective treatment planning provides a clinician with intuitive insight into the treatment planning process by being able to inspect a wide range of potential treatment plans having different trade-offs between coverage of the target organs and sparing of the OARs. We have developed a GPU-based parallel version of a previously introduced bi-objective treatment planning method 8 that optimizes for the worst target and sparing criterion. Furthermore, the optimization model has been adjusted to provide better results, particularly improving values of DV indices that are not the worst criterion. This bi-objective treatment planning method is now capable of producing a set of high-quality solutions, each with a different trade-off between the coverage of the target organs and sparing of the OARs, optimized for 100 000 DC points, in approximately 3 minutes, making it efficient enough to be used in a time-constrained clinical setting.
